3rd generation EGFR TKIs, osimertinib
Osimertinib, Phase I
Osimertinib, Phase II
RR: 61%. PFS 9.6 mo.
T790M-, RR 21%, PFS 2.8 mo
N=253
RR: 70%. PFS: 9.9 mo
N=210
(40% brain M1)
Jänne NEJM 2015, Goss Lancet Oncol 2016